AlbertP. S., MallouhC., NagamatsuG. R.: Transitional cell carcinoma of the prostate. Urology, 2; 128–130 (1973).
2.
AlexanderS. J., LeeS. S., BekhradA.: Transitional cell carcinoma of the prostate: response to treatment with cisplatinum and cyclophosphamide. J. Urol., 131; 975–977 (1984).
3.
BelterL. F., DodsonA. L.jr.: Papillomatosis and papillary adenocarcinoma of the prostatic duct: a case report. J. Urol., 104; 880–883 (1970).
4.
CatalonaW. J., KadmonD., MartinS. A.: Surgical considerations in treatment of intraductal carcinoma of the prostate. J. Urol., 120; 259–261 (1978).
5.
DexeusF. H., LogothetisC. J., SamuelsM. L., AyalaA. G., HossanE.: Complete responses in metastatic transitional cell carcinoma of the prostate with cisplatin regimens. J. Urol., 137; 122–125 (1987).
6.
DrakeW. M., BurrowsS.: Papillary primary duct adenocarcinoma of the prostate. J. Urol., 107; 825–827 (1972).
7.
KopelsonG., HariasidisL., RomasN. A., VeenemaR. J., TannenbaumM.: Periurethral prostatic duct carcinoma clinical features and treatment results. Cancer, 42; 2894–2902 (1978).
8.
MincioneP. Q., Di CelloV., NigiL., DurvalA., SaltuttiC.: Grade 2 urethroprostatic papillary urothelial carcinoma with positive urinary cytology. J. Urol., 133; 1038–1039 (1985).
9.
NicolòG., SalviS., MussoC., D'AmoreE.: Carcinoma latente della prostata. Uno studio autoptico di 100 casi. Pathologica, 78; 579–591 (1986).